Position in AVBP
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$39,144,068
+$5,005,418 QoQ
Shares Held
1,696,752
0.0% QoQ
Ownership
3.64%
of shares outstanding
% of Portfolio
1.97%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AVBP Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Sofinnova Investments, Inc. holds $1,140,503,369 across 48 Biotechnology names. AVBP ranks #10 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
598,327 | $113,113,719 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,793,987 | $112,402,097 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
2,113,551 | $81,350,577 | |
| 4 | RARE |
Ultragenyx Pharmaceutical Inc.
|
3,145,888 | $65,906,353 | |
| 5 | RAPP |
Rapport Therapeutics, Inc.
|
1,904,408 | $59,588,926 | |
| 6 | INSM |
INSMED Inc
|
346,075 | $56,590,184 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
781,982 | $44,174,163 | |
| 8 | CELC |
Celcuity Inc.
|
366,175 | $41,795,214 |
All Filings in AVBP
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $39,144,068 | 1,696,752 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $34,138,650 | 1,696,752 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $31,305,074 | 1,696,752 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $36,938,291 | 1,696,752 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $31,372,944 | 1,696,752 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $45,201,473 | 1,696,752 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $39,873,672 | 1,696,752 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $31,474,749 | 1,696,752 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $30,303,990 | 1,696,752 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||